A phase III clinical trial of the DCVax®-L cancer vaccine, conducted @WilmotCancer and other centers internationally, has shown the first meaningful survival extension for patients #URochesterResearch Tweet added by University of Rochester @UofR

University of Rochester

2 years

A phase III clinical trial of the DCVax®-L cancer vaccine, conducted @WilmotCancer and other centers internationally, has shown the first meaningful survival extension for patients #URochesterResearch

Personalized Immune Therapy Extended Survival in Patients with Aggressive Brain Cancer

A phase III clinical trial of the DCVax®-L cancer vaccine, conducted at the Wilmot Cancer Institute and other centers internationally, has shown the first meaningful survival extension for patients...

www.urmc.rochester.edu

115

Replies

john s

@johnjoescanlan

2 years

@UofR @WilmotCancer Unfortunately there is very little media coverage of this incredible medical breakthrough, which is quite disturbing. Please spread the word as people right now could have their one and ONLY LIFE prolonged and not have to suffer the effects of Chemo.